Twirla Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Twirla Availability in 2026

If your patients have been reporting difficulty filling Twirla prescriptions, they're not wrong. While Twirla (Levonorgestrel/Ethinyl Estradiol transdermal system) is not formally in shortage, its limited distribution, single-source manufacturing, and variable insurance coverage create real access barriers for patients.

This briefing covers the current state of Twirla availability, prescribing implications, cost considerations, and tools you can use to help your patients access this medication.

Timeline: Twirla's Path to Market

Understanding Twirla's history helps explain its current market position:

• 2015: Agile Therapeutics submits initial NDA for Twirla (then known as AG200-15)
• 2016: FDA issues first Complete Response Letter (CRL) citing manufacturing deficiencies
• 2017: Second CRL issued — quality adhesion test methods and third-party manufacturer issues
• 2020 (February): FDA approves Twirla with a boxed warning regarding BMI ≥30 and cigarette smoking
• 2020 (Q4): Commercial launch in the U.S.
• 2023: Twirla made available through MMCAP Infuse (26,000+ member facilities) and FPA Women's Health
• 2026: Twirla remains a single-source brand-name product with no generic competitor

The lengthy approval process and limited commercial footprint have contributed to lower awareness and adoption among prescribers and pharmacies.

Prescribing Implications

Clinical Profile

Twirla delivers 120 mcg Levonorgestrel and 30 mcg Ethinyl Estradiol per 24 hours via transdermal patch. Key prescribing considerations:

• BMI restriction: Contraindicated in patients with BMI ≥30 kg/m². Reduced efficacy demonstrated in women with BMI 25–30 kg/m².
• Lower estrogen dose: Twirla delivers 30 mcg EE/day vs. Xulane's 35 mcg EE/day, which may be clinically relevant for patients sensitive to estrogen-related side effects.
• Boxed warning: Cigarette smoking and serious cardiovascular events; contraindicated in BMI ≥30 kg/m².
• VTE risk: In the Phase 3 clinical trial, 4 patients experienced VTE — all had BMI >30 kg/m².
• Application sites: Buttock, abdomen, or upper torso (not breast).

For complete prescribing information including drug interactions and side effects, refer to the full PI at twirla.com.

Drug Interactions of Note

As with all CHCs, be aware of interactions that may reduce contraceptive efficacy:

• CYP3A4 inducers: Rifampin, Phenytoin, Carbamazepine, Phenobarbital, Topiramate, Felbamate, Oxcarbazepine, Bosentan, Griseofulvin
• St. John's Wort: Significant CYP3A4 inducer — contraceptive failure risk
• Hepatitis C antivirals: Ombitasvir/Paritaprevir/Ritonavir combinations are contraindicated due to ALT elevation risk
• Lamotrigine: CHCs may decrease Lamotrigine levels — monitor seizure control

Current Availability Picture

Twirla is not on the FDA or ASHP drug shortage lists as of early 2026. However, practical availability remains inconsistent:

• Chain pharmacies: Most large chains (CVS, Walgreens, Rite Aid) do not routinely stock Twirla unless there is regular local demand. Automated inventory systems deprioritize low-volume products.
• Independent pharmacies: More likely to special-order on request and maintain stock for regular patients.
• Mail-order: Available through most PBM mail-order programs.
• Telehealth: Platforms like Pandia Health and Nurx prescribe and deliver Twirla directly (~$50/month).
• Specialty networks: Available through MMCAP Infuse for qualified facilities.

Cost and Access Considerations

Cost is a significant factor in patient adherence and prescribing decisions:

• Retail cash price: $250–$290/month
• With discount coupons (GoodRx/SingleCare): $200–$210/month
• Manufacturer savings card: $0 first month, $25/month for subsequent fills (commercially insured patients; not valid for Medicare/Medicaid)
• ACA mandate: Most commercial plans must cover at least one contraceptive per FDA category at $0 cost-sharing. If a plan covers Xulane as the preferred patch, a formulary exception request may be needed for Twirla.

For detailed savings information to share with patients, see our patient savings guide or our provider guide to helping patients save.

Tools and Resources for Providers

Medfinder for Providers

Medfinder helps providers and patients identify pharmacies with Twirla in stock. You can direct patients to the platform or use it yourself when writing prescriptions to select a pharmacy likely to have the medication available.

Prior Authorization Support

When insurance requires PA for Twirla, consider documenting:

• Clinical rationale for the lower-estrogen formulation (e.g., estrogen sensitivity, prior side effects on higher-dose options)
• Patient's BMI (within approved range)
• Failure of or intolerance to preferred formulary alternatives
• Patient preference for a transdermal delivery system (adherence considerations)

Manufacturer Resources

Agile Therapeutics provides:

• HCP portal at twirla.com/hcp
• Savings program enrollment at twirla.com/savings-program
• Phone support: 1-866-747-7108

Alternative Prescribing Options

When Twirla is unavailable or not covered, consider these alternatives:

• Xulane (Norelgestromin/EE patch): Most direct alternative. Higher estrogen dose. Generic — more affordable and widely stocked.
• NuvaRing/EluRyng (Etonogestrel/EE vaginal ring): Non-daily option for patients who prefer not to use a patch.
• Oral contraceptive pills: Many contain Levonorgestrel/EE — the same hormones as Twirla. Most affordable option.
• LARCs: IUDs and implants for patients open to long-acting methods.

See our alternatives guide for patient-facing information you can share.

Looking Ahead

Several developments could affect Twirla's availability and market position:

• Generic competition: No generic is currently approved or publicly in development. The Skinfusion® transdermal technology may present barriers to generic entry.
• Xulane Lo: A lower-estrogen version of Xulane in development could directly compete with Twirla's positioning.
• Regulatory: FDA-required post-marketing VTE study is ongoing, which could affect labeling.

Final Thoughts

Twirla fills a real clinical niche as the only lower-dose contraceptive patch. But access remains a challenge for patients. By leveraging tools like Medfinder, manufacturer savings programs, and strategic pharmacy selection, providers can help patients access this medication more consistently.

For a practical guide on helping patients navigate availability, see our companion post: How to help your patients find Twirla in stock.